Efficacy of targeted therapy for lung cancer patients included in IMPRESS-Norway, and precision cancer medicine in hard-to-treat rare cancers in the MATRIX-RARE study.
Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo ECet al.(2025) Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma Nat Commun, 16(1), 7717 DOI 10.1038/s41467-025-63091-0, PubMed 40830141
Henkel PS, Aas E, Russnes HG, Dyvik I, Fagereng GL, Helland Å, Røgenes H, Lien TG, Pedersen K(2025) Microcosting Study of Genomic Profiling for Precision Cancer Medicine: Application from the National Infrastructure for Precision Diagnostics in Norway J Mol Diagn, 27(10), 945-953 DOI 10.1016/j.jmoldx.2025.06.006, PubMed 40712993
Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS(2025) Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient Cell Death Dis, 16(1), 555 DOI 10.1038/s41419-025-07884-7, PubMed 40701968
